Profiles

Adele Holloway

UTAS Home Dr Adele Holloway

Adele Holloway

Associate Head, Learning and Teaching

Room 337a , Medical Science 2 (MS2)

+61 3 6226 2670 (phone)

A.F.Holloway@utas.edu.au

Genes contain the instructions that tell our cells which proteins to manufacture. These proteins, in turn, are the building blocks of our body and they regulate the processes that allow us to sense our environment and respond to it, digest food, fight off diseases, grow, reproduce and carry out the range of other functions that are essential to our survival.

Our knowledge of genes has grown considerably in recent years, especially with major research initiatives like the Human Genome Project. We now know much more about the range of genes, what they do, how they vary from person to person, and what role they play in disease. An area of growing interest, however, is the process by which the genes themselves are regulated.

Dr Adele Holloway, Senior Lecturer in the School of Medicine, investigates the role of transcription factors and epigenetic mechanisms in the regulation of gene expression. Transcription factors are proteins that act like switches, increasing or decreasing the expression of particular genes. Epigenetic mechanisms are processes that modify the chemistry or structure of the DNA that makes up genes.

‘Genes are like the notes in a musical score,’ Dr Holloway says. ‘But equally important are the instructions that tell the musician how fast or how slow to play, when to pause, and how to coordinate with the other musicians.’

The role of transcription factors and epigenetic mechanisms in making sure the right genes are switched on or off at the right time is vital for the normal behaviour of cells, and therefore for our health. A focus of Dr Holloway’s work is to understand how this process can go wrong in some diseases, especially in cancer.

Cancer is a disease in which the normal regulation of a cell is disrupted, allowing it to divide and multiply in an uncontrolled way. Dr Holloway is currently studying prostate cancer and leukaemia and, in particular, the role of transcription factors and epigenetic mechanisms in causing cancerous cells to become metastatic, that is to spread to different parts of the body.

‘By better understanding these changes, we might be able to develop better diagnostic methods and treatments. Ultimately, we hope to be able to intervene to stop cancers from becoming metastatic.’

Dr Holloway’s team uses computational biology to do genome-wide analyses and molecular biology techniques to look at the role of individual genes. ‘What we are finding is that the more we know, the more we appreciate the level of complexity. Gene regulation is an incredibly intricate process.’

Dr Holloway is also passionate about the teaching of research skills. As the Associate Head of Learning and Teaching at the School of Medicine, she is currently investigating how research skills are taught and how the curriculum can be improved across various disciplines. By surveying students, getting their feedback, and analysing responses, she aims to get a better understanding of the skills students are acquiring and how this matches up with expectations.

‘Good research skills are important not just to research scientists but also for a range of professionals like paramedics, pharmacists, and medical graduates,’ Dr Holloway says. ‘Having the skills to understand research, how it is done and what the results mean is central to making good evidence-based judgements and keeping up with best practice in their fields.’

Dr Holloway is a molecular biologist in the School of Medicine, Faculty of Health with a research interest in gene regulation and epigenetics.

Biography

Before joining the University of Tasmania, Dr Holloway was a Postdoctoral Research Fellow at the Hanson Centre for Cancer Research (Adelaide) and at the John Curtin School of Medical Research, ANU (Canberra).

Career summary

Qualifications

  • PhD, University of Tasmania, Australia. 1997
  • BSc (1st Class Hons), University of Tasmania, Australia. 1992

Memberships

Professional practice

Dr Holloway is a member of the Australian Society for Medical Research and the Australian Epigenetic Alliance.

Teaching

molecular biology, biochemistry

Teaching expertise

Dr Holloway is co-ordinator of the Bachelor of Medical Research. She has expertise in the areas of undergraduate biochemistry and molecular biology teaching, and as a supervisor of both Honours and PhD students.

Teaching responsibility

Research Appointments

  • NHMRC Career Development Fellowship Panel (2014-2015)
  • Conference Chair Australian Epigenetics Alliance Conference (2015)
  • Australian Epigenetic Alliance, State Representative
  • NHMRC Grant Review Panel (2006-7, 2010-12)
  • Lorne Genome Conference Organising committee (2011-2013)
  • AMATA Conference Organising committee (2010)
  • ASMR Tasmanian Medical Research Week Committee (2007-2010, 2014- present)

View more on AssocProf Adele Holloway in WARP

Expertise

  • regulation of gene expression
  • epigenetic mechanisms
  • cancer gene regulation
  • cancer biology
  • immune regulation

Research Themes

Dr Holloway's research aligns to the University's research theme of Better Health. Her research interests are focused on understanding how genes are regulated in response to cellular signals, with a particular interest in the immune system.

This work is investigating the role of transcription factors and epigenetic mechanisms in the regulation of gene expression. She is also conducting research aimed at understanding how disruption of normal gene expression programs contributes to the development and progression of disease such as cancer, with a particular focus on leukaemia and prostate cancer.

Collaboration

Dr Holloway collaborates with a number of fellow researchers within the University of Tasmania as well as inter state.

  • Assoc Prof Joanne Dickinson, Menzies Institute for Medical Research, University of Tasmania
  • Dr Kate Brettingham-Moore, School of Medicine, University of Tasmania
  • Dr Jac Charlesworth, Menzies Institute for Medical Research, University of Tasmania
  • Assoc Prof Sudha Rao, University of Canberra, ACT
  • Dr Phillippa Taberlay, Garvan Institute for Medical Research, NSW

Current projects

  • Role of RUNX transcription factors in leukaemia and other cancers
  • Transcriptional and epigenetic regulation of gene expression prostate cancer
  • Inherited determinants of epigenetic profiles and their role in cancer development
  • Regulation of gene expression in the immune system

Fields of Research

  • Biochemistry and cell biology (310199)
  • Epigenetics (incl. genome methylation and epigenomics) (310504)
  • Cancer genetics (321103)
  • Cancer cell biology (321101)
  • Molecular targets (321108)
  • Gene expression (incl. microarray and other genome-wide approaches) (310505)
  • Cell metabolism (310103)
  • Genome structure and regulation (310508)
  • Medical genetics (excl. cancer genetics) (320213)
  • Central nervous system (320903)
  • Oncology and carcinogenesis (321199)
  • Respiratory diseases (320103)
  • Epidemiology (420299)
  • Cellular nervous system (320902)
  • Cellular immunology (320404)
  • Educational technology and computing (390405)
  • Immunology (320499)
  • Solid tumours (321111)
  • Basic pharmacology (321401)
  • Health services and systems (420399)
  • Cell development, proliferation and death (310102)
  • Genetics (310599)
  • Haematology (320102)
  • Tumour immunology (320409)
  • Clinical sciences (320299)
  • Other biological sciences (319999)
  • Education assessment and evaluation (390402)
  • Analytical biochemistry (310101)
  • Ophthalmology (321201)
  • Medicine, nursing and health curriculum and pedagogy (390110)
  • Sensory systems (320907)
  • Radiation therapy (321110)
  • Preventative health care (420605)
  • Genomics (310509)
  • Medical biochemistry and metabolomics (320599)
  • Anaesthesiology (320201)
  • Cancer diagnosis (321102)
  • Medical bacteriology (320701)
  • Cellular interactions (incl. adhesion, matrix, cell wall) (310105)
  • Bioinformatic methods development (310201)
  • Cancer therapy (excl. chemotherapy and radiation therapy) (321104)
  • Haematological tumours (321106)
  • Cardiology (incl. cardiovascular diseases) (320101)
  • Aboriginal and Torres Strait Islander public health and wellbeing (450417)

Research Objectives

  • Clinical health (200199)
  • Expanding knowledge in the environmental sciences (280111)
  • Expanding knowledge in the biological sciences (280102)
  • Expanding knowledge in the health sciences (280112)
  • Disease distribution and transmission (incl. surveillance and response) (200404)
  • Teaching and instruction technologies (160304)
  • Men's health (200504)
  • Treatment of human diseases and conditions (200105)
  • Diagnosis of human diseases and conditions (200101)
  • Learner and learning (160199)
  • Assessment, development and evaluation of curriculum (160301)
  • Expanding knowledge in the biomedical and clinical sciences (280103)
  • Expanding knowledge in the physical sciences (280120)
  • Human pharmaceutical products (240899)
  • Efficacy of medications (200102)

Publications

Dr Holloway's research has made significant contributions to our understanding of regulation of gene expression by transcription factors and chromatin. Her current research in this area continues a track record in the field which has been published in highly regarded journals in the Biochemistry and Molecular Biology Field, including Journal of Biological Chemistry, Journal of Experimental Medicine,Nucleic Acids Research and Molecular and Cellular Biology. She has also more recently made important contributions to our understanding of transcription factor driven and epigenetic regulation of gene expression in cancer.

Total publications

62

Highlighted publications

(5 outputs)
YearTypeCitationAltmetrics
2005Journal ArticleBrettingham-Moore KH, Rao S, Jeulich T, Shannon MF, Holloway AF, 'GM-CSF promoter chromatin remodelling and gene transcription display distinct signal and transcription factor requirements', Nucleic Acids Research, 33, (1) pp. 225-234. ISSN 0305-1048 (2005) [Refereed Article]

DOI: 10.1093/nar/gki161 [eCite] [Details]

Citations: Scopus - 30Web of Science - 26

Co-authors: Brettingham-Moore KH

Tweet

2004Journal ArticleHenderson A, Holloway AF, Reeves R, Tremethick DJ, 'Recruitment of SW1/SNF to the human immunodeficiency virus type 1 promotor', Molecular and Cellular Biology, 24, (1) pp. 389-397. ISSN 0270-7306 (2004) [Refereed Article]

DOI: 10.1128/MCB.24.1.389-397.2004 [eCite] [Details]

Citations: Scopus - 67Web of Science - 61

Tweet

2003Journal ArticleHolloway AF, Rao S, Chen X, Shannon MF, 'Changes in chromatin accessibility across the GM-CSF promoter upon T cell activation are dependent on nuclear factor kappaB proteins', Journal of Experimental Medicine, 197, (4) pp. 413-423. ISSN 0022-1007 (2003) [Refereed Article]

DOI: 10.1084/jem.20021039 [eCite] [Details]

Citations: Scopus - 60Web of Science - 58

Tweet

2002Journal ArticleHolloway AF, Rao S, Shannon MF, 'Regulation of cytokine gene transcription in the immune system', Molecular Immunology, 38, (8) pp. 567-580. ISSN 0161-5890 (2002) [Refereed Article]

DOI: 10.1016/S0161-5890(01)00094-3 [eCite] [Details]

Citations: Scopus - 52Web of Science - 47

Tweet

2000Journal ArticleHolloway AF, Occhiodoro F, Mittler G, Meisterernst MF, Shannon MF, 'Functional interaction between the HIV transactivator Tat and the transcriptional coactivator PC4 in T cells', Journal of Biological Chemistry, 275, (28) pp. 21668-21677. ISSN 0021-9258 (2000) [Refereed Article]

DOI: 10.1074/jbc.M909058199 [eCite] [Details]

Citations: Scopus - 16Web of Science - 17

Tweet

Journal Article

(35 outputs)
YearCitationAltmetrics
2021Wilson A, Howitt S, Holloway A, Williams A-M, Higgins D, 'Factors affecting paramedicine students' learning about evidence-based practice: a phenomenographic study', BMC Medical Education, 21, (1) pp. 1-12. ISSN 1472-6920 (2021) [Refereed Article]

DOI: 10.1186/s12909-021-02490-5 [eCite] [Details]

Co-authors: Williams A-M

Tweet

2020Wilkinson EJ, Woodworth AM, Parker M, Phillips JL, Malley RC, et al., 'Epigenetic regulation of the ITGB4 gene in prostate cancer', Experimental Cell Research, 392, (2) pp. 1-10. ISSN 0014-4827 (2020) [Refereed Article]

DOI: 10.1016/j.yexcr.2020.112055 [eCite] [Details]

Co-authors: Wilkinson EJ; Woodworth AM; Parker M; Phillips JL; Malley RC; Dickinson JL

Tweet

2019Sutton LP, Jeffreys SA, Phillips JL, Taberlay PC, Holloway AF, et al., 'DNA methylation changes following DNA damage in prostate cancer cells', Epigenetics, 14, (10) pp. 989-1002. ISSN 1559-2294 (2019) [Refereed Article]

DOI: 10.1080/15592294.2019.1629231 [eCite] [Details]

Citations: Scopus - 6Web of Science - 11

Co-authors: Sutton LP; Jeffreys SA; Phillips JL; Taberlay PC; Ambrose M; Young A; Berry R; Brettingham-Moore KH

Tweet

2018De Paoli-Iseppi R, Prentice L, Marthick JR, Thomson R, Holloway AF, et al., 'Multiple endocrine neoplasia type 1: clinical correlates of MEN1 gene methylation', Pathology, 50, (6) pp. 622-628. ISSN 0031-3025 (2018) [Refereed Article]

DOI: 10.1016/j.pathol.2018.05.006 [eCite] [Details]

Citations: Scopus - 3Web of Science - 4

Co-authors: De Paoli-Iseppi R; Prentice L; Marthick JR; Thomson R; Dickinson JL; Burgess J

Tweet

2018Phillips JL, Taberlay PC, Woodworth AM, Hardy K, Brettingham-Moore KH, et al., 'Distinct mechanisms of regulation of the ITGA6 and ITGB4 genes by RUNX1 in myeloid cells', Journal of Cellular Physiology, 233, (4) pp. 3439-3453. ISSN 0021-9541 (2018) [Refereed Article]

DOI: 10.1002/jcp.26197 [eCite] [Details]

Citations: Scopus - 7Web of Science - 7

Co-authors: Phillips JL; Taberlay PC; Woodworth AM; Brettingham-Moore KH; Dickinson JL

Tweet

2017Woodworth AM, Holloway AF, 'The role of epigenetic regulation in transcriptional memory in the immune system', Advances in Protein Chemistry and Structural Biology, 106 pp. 43-69. ISSN 1876-1623 (2017) [Refereed Article]

DOI: 10.1016/bs.apcsb.2016.09.002 [eCite] [Details]

Citations: Scopus - 8Web of Science - 9

Co-authors: Woodworth AM

Tweet

2016Atashrazm F, Lowenthal RM, Dickinson JL, Holloway AF, Woods GM, 'Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo', OncoTarget, 7, (29) pp. 46028-46041. ISSN 1949-2553 (2016) [Refereed Article]

DOI: 10.18632/oncotarget.10016 [eCite] [Details]

Citations: Scopus - 14Web of Science - 12

Co-authors: Lowenthal RM; Dickinson JL; Woods GM

Tweet

2016Cazaly E, Thomson R, Marthick JR, Holloway AF, Charlesworth J, et al., 'Comparison of pre-processing methodologies for Illumina 450k methylation array data in familial analyses', Clinical Epigenetics, 8, (1) Article 75. ISSN 1868-7083 (2016) [Refereed Article]

DOI: 10.1186/s13148-016-0241-2 [eCite] [Details]

Citations: Scopus - 5Web of Science - 4

Co-authors: Cazaly E; Thomson R; Marthick JR; Charlesworth J; Dickinson JL

Tweet

2015Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Dickinson JL, 'Fucoidan and cancer: a multifunctional molecule with anti-tumor potential', Marine Drugs, 13, (4) pp. 2327-2346. ISSN 1660-3397 (2015) [Refereed Article]

DOI: 10.3390/md13042327 [eCite] [Details]

Citations: Scopus - 134Web of Science - 133

Co-authors: Lowenthal RM; Woods GM; Dickinson JL

Tweet

2015Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Karpiniec SS, et al., 'Fucoidan suppresses the growth of human acute promyelocytic leukemia cells in vitro and in vivo', Journal of Cellular Physiology, 231, (3) pp. 688-697. ISSN 0021-9541 (2015) [Refereed Article]

DOI: 10.1002/jcp.25119 [eCite] [Details]

Citations: Scopus - 23Web of Science - 21

Co-authors: Lowenthal RM; Woods GM; Dickinson JL

Tweet

2015Brettingham-Moore KH, Taberlay PC, Holloway AF, 'Interplay between transcription factors and the epigenome: insight from the role of RUNX1 in leukemia', Frontiers in Immunology, 6 Article 499. ISSN 1664-3224 (2015) [Refereed Article]

DOI: 10.3389/fimmu.2015.00499 [eCite] [Details]

Citations: Scopus - 18Web of Science - 18

Co-authors: Brettingham-Moore KH; Taberlay PC

Tweet

2015Cazaly E, Charlesworth J, Dickinson JL, Holloway AF, 'Genetic determinants of epigenetic patterns: providing insight into disease', Molecular Medicine, 21 pp. 400-409. ISSN 1076-1551 (2015) [Refereed Article]

DOI: 10.2119/molmed.2015.00001 [eCite] [Details]

Citations: Scopus - 8Web of Science - 8

Co-authors: Cazaly E; Charlesworth J; Dickinson JL

Tweet

2015Chin SP, Marthick JR, West AC, Short AK, Chuckowree J, et al., 'Regulation of the ITGA2 gene by epigenetic mechanisms in prostate cancer', The Prostate, 75, (7) pp. 723-734. ISSN 0270-4137 (2015) [Refereed Article]

DOI: 10.1002/pros.22954 [eCite] [Details]

Citations: Scopus - 15Web of Science - 14

Co-authors: Chin SP; Marthick JR; West AC; Short AK; Chuckowree J; Polanowski AM; Thomson RJ; Dickinson JL

Tweet

2015Qadi A, Taberlay PC, Phillips JL, Young A, West AC, et al., 'The leukemia inhibitory factor receptor gene is a direct target of RUNX1', Journal of Cellular Biochemistry, 117, (1) pp. 49-58. ISSN 0730-2312 (2015) [Refereed Article]

DOI: 10.1002/jcb.25246 [eCite] [Details]

Citations: Scopus - 2Web of Science - 2

Co-authors: Taberlay PC; Phillips JL; Young A; West AC; Brettingham-Moore KH; Dickinson JL

Tweet

2014Herbert KJ, Holloway A, Cook AL, Chin SP, Snow ET, 'Arsenic exposure disrupts epigenetic regulation of SIRT1 in human keratinocytes', Toxicology and Applied Pharmacology, 281, (1) pp. 136-145. ISSN 0041-008X (2014) [Refereed Article]

DOI: 10.1016/j.taap.2014.09.012 [eCite] [Details]

Citations: Scopus - 23Web of Science - 17

Co-authors: Herbert KJ; Cook AL; Chin SP; Snow ET

Tweet

2014Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, et al., 'RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization', BMC Cancer, 14 Article 808. ISSN 1471-2407 (2014) [Refereed Article]

DOI: 10.1186/1471-2407-14-808 [eCite] [Details]

Citations: Scopus - 19Web of Science - 17

Co-authors: Young A; Berry R; Blackburn NB; Dickinson JL; Phillips JL; Brettingham-Moore KH

Tweet

2014Zhou Y, Simpson Jr S, Holloway AF, Charlesworth J, van der Mei I, et al., 'The potential role of epigenetic modifications in the heritability of multiple sclerosis', Multiple Sclerosis Journal, 20, (2) pp. 135-140. ISSN 1352-4585 (2014) [Refereed Article]

DOI: 10.1177/1352458514520911 [eCite] [Details]

Citations: Scopus - 22Web of Science - 23

Co-authors: Zhou Y; Simpson Jr S; Charlesworth J; van der Mei I; Taylor BV

Tweet

2013Lim PS, Li J, Holloway AF, Rao S, 'Epigenetic regulation of inducible gene expression in the immune system', Immunology, 139, (3) pp. 285-293. ISSN 0019-2805 (2013) [Refereed Article]

DOI: 10.1111/imm.12100 [eCite] [Details]

Citations: Scopus - 38Web of Science - 37

Tweet

2012Poke FS, Upcher WR, Sprod OR, Young A, Brettingham-Moore KH, et al., 'Depletion of c-Rel from cytokine gene promoters is required for chromatin reassembly and termination of gene responses to T cell activation', PLoS One, 7, (7) Article e41734. ISSN 1932-6203 (2012) [Refereed Article]

DOI: 10.1371/journal.pone.0041734 [eCite] [Details]

Citations: Scopus - 4Web of Science - 4

Co-authors: Poke FS; Sprod OR; Young A; Brettingham-Moore KH

Tweet

2011Chin SP, Dickinson JL, Holloway AF, 'Epigenetic regulation of prostate cancer', Clinical Epigenetics, 2, (2) pp. 151-169. ISSN 1868-7075 (2011) [Refereed Article]

DOI: 10.1007/s13148-011-0041-7 [eCite] [Details]

Citations: Scopus - 25Web of Science - 20

Co-authors: Chin SP; Dickinson JL

Tweet

2011Hale DM, Ray S, Leung JY, Holloway AF, Chung RS, et al., 'Olfactory ensheathing cells moderate nuclear factor kappaB translocation in astrocytes ', Molecular and Cellular Neuroscience, 46, (1) pp. 213-221. ISSN 1044-7431 (2011) [Refereed Article]

DOI: 10.1016/j.mcn.2010.09.004 [eCite] [Details]

Citations: Scopus - 9Web of Science - 8

Co-authors: Hale DM; Ray S; Leung JY; Chung RS; West AK; Chuah MI

Tweet

2010Oakford PC, James SR, Qadi A, West AC, Ray SN, et al., 'Transcriptional and epigenetic regulation of the GM-CSF promoter by RUNX1', Leukemia Research, 34, (9) pp. 1203-1213. ISSN 0145-2126 (2010) [Refereed Article]

DOI: 10.1016/j.leukres.2010.03.029 [eCite] [Details]

Citations: Scopus - 11Web of Science - 11

Co-authors: Oakford PC; West AC; Ray SN

Tweet

2010Poke FS, Qadi A, Holloway AF, 'Reversing Aberrant Methylation Patterns in Cancer', Current Medicinal Chemistry, 17, (13) pp. 1246-1254. ISSN 0929-8673 (2010) [Refereed Article]

DOI: 10.2174/092986710790936329 [eCite] [Details]

Citations: Scopus - 11Web of Science - 10

Co-authors: Poke FS

Tweet

2008Brettingham-Moore KH, Sprod OR, Chen X, Oakford PC, Shannon MF, et al., 'Determinants of a transcriptionally competent environment at the GM-CSF promoter', Nucleic Acids Research, 36, (8) pp. 2639-2653. ISSN 0305-1048 (2008) [Refereed Article]

DOI: 10.1093/nar/gkn117 [eCite] [Details]

Citations: Scopus - 16Web of Science - 14

Co-authors: Brettingham-Moore KH; Sprod OR; Oakford PC

Tweet

2007Holloway AF, Oakford PC, 'Targeting Epigentic Modifiers in Cancer', Current Medicinal Chemistry, 14, (24) pp. 2540-2547. ISSN 0929-8673 (2007) [Refereed Article]

DOI: 10.2174/092986707782023271 [eCite] [Details]

Citations: Scopus - 16Web of Science - 13

Co-authors: Oakford PC

Tweet

2006Shannon MF, Chen X, Brettingham-Moore KH, Holloway AF, 'Chromatin remodelling: Distinct molecular events during differentiation and activation of T cells', Current Immunology Reviews, 2, (3) pp. 273-289. ISSN 1573-3955 (2006) [Refereed Article]

DOI: 10.2174/157339506778018587 [eCite] [Details]

Citations: Scopus - 1

Co-authors: Brettingham-Moore KH

Tweet

2005Brettingham-Moore KH, Rao S, Jeulich T, Shannon MF, Holloway AF, 'GM-CSF promoter chromatin remodelling and gene transcription display distinct signal and transcription factor requirements', Nucleic Acids Research, 33, (1) pp. 225-234. ISSN 0305-1048 (2005) [Refereed Article]

DOI: 10.1093/nar/gki161 [eCite] [Details]

Citations: Scopus - 30Web of Science - 26

Co-authors: Brettingham-Moore KH

Tweet

2004Henderson A, Holloway AF, Reeves R, Tremethick DJ, 'Recruitment of SW1/SNF to the human immunodeficiency virus type 1 promotor', Molecular and Cellular Biology, 24, (1) pp. 389-397. ISSN 0270-7306 (2004) [Refereed Article]

DOI: 10.1128/MCB.24.1.389-397.2004 [eCite] [Details]

Citations: Scopus - 67Web of Science - 61

Tweet

2003Holloway AF, Rao S, Chen X, Shannon MF, 'Changes in chromatin accessibility across the GM-CSF promoter upon T cell activation are dependent on nuclear factor kappaB proteins', Journal of Experimental Medicine, 197, (4) pp. 413-423. ISSN 0022-1007 (2003) [Refereed Article]

DOI: 10.1084/jem.20021039 [eCite] [Details]

Citations: Scopus - 60Web of Science - 58

Tweet

2002Chung RS, Holloway AF, Eckhardt BL, Harris JA, Vickers JC, et al., 'Sheep have an unusual variant of the brain-specific metallothionein, metallothionein-III', Biochemical Journal, 365 pp. 323-328. ISSN 0264-6021 (2002) [Refereed Article]

DOI: 10.1042/BJ20011751 [eCite] [Details]

Citations: Scopus - 20Web of Science - 18

Co-authors: Chung RS; Harris JA; Vickers JC; Chuah MI; West AK

Tweet

2002Holloway AF, Rao S, Shannon MF, 'Regulation of cytokine gene transcription in the immune system', Molecular Immunology, 38, (8) pp. 567-580. ISSN 0161-5890 (2002) [Refereed Article]

DOI: 10.1016/S0161-5890(01)00094-3 [eCite] [Details]

Citations: Scopus - 52Web of Science - 47

Tweet

2000Holloway AF, Occhiodoro F, Mittler G, Meisterernst MF, Shannon MF, 'Functional interaction between the HIV transactivator Tat and the transcriptional coactivator PC4 in T cells', Journal of Biological Chemistry, 275, (28) pp. 21668-21677. ISSN 0021-9258 (2000) [Refereed Article]

DOI: 10.1074/jbc.M909058199 [eCite] [Details]

Citations: Scopus - 16Web of Science - 17

Tweet

1997Holloway AF, Stennard FA, Dziegielewska KM, Weller WL, West AK, 'Localisation and expression of metallothionein immunoreactivity in the developing sheep brain', International Journal of Developmental Neuroscience, 15, (2) pp. 195-203. ISSN 0736-5748 (1997) [Refereed Article]

DOI: 10.1016/S0736-5748(96)00091-3 [eCite] [Details]

Citations: Scopus - 26Web of Science - 27

Co-authors: Stennard FA; Dziegielewska KM; Weller WL; West AK

Tweet

1997Holloway AF, Stennard FA, West AK, 'Human metallothionein gene MT1L mRNA is present in several human tissues but is unlikely to produce a metallothionein protein', FEBS Letters, 404, (1) pp. 41-44. ISSN 0014-5793 (1997) [Refereed Article]

DOI: 10.1016/S0014-5793(97)00082-3 [eCite] [Details]

Citations: Scopus - 4Web of Science - 5

Co-authors: Stennard FA; West AK

Tweet

1997Skabo SJ, Holloway AF, West AK, Chuah MI, 'Metallothioneins 1 and 2 are expressed in the olfactory mucosa of mice in untreated animals and during the regeneration of the epithelial layer', Biochemical and Biophysical Research Communications, 232, (1) pp. 136-142. ISSN 0006-291X (1997) [Refereed Article]

DOI: 10.1006/bbrc.1997.6243 [eCite] [Details]

Citations: Scopus - 15Web of Science - 17

Co-authors: Skabo SJ; West AK; Chuah MI

Tweet

Chapter in Book

(6 outputs)
YearCitationAltmetrics
2013Chin PS, Dickinson JL, Holloway AF, 'Integrins in Prostate Cancer Invasion and Metastasis', Advances in Prostate Cancer, InTech, Gerhard Hamilton (ed), Croatia, pp. 621-640. ISBN 978-953-51-0932-7 (2013) [Research Book Chapter]

DOI: 10.5772/45948 [eCite] [Details]

Co-authors: Chin PS; Dickinson JL

Tweet

2012Apps LD, Holloway AF, 'The role of Chromatin in inducible gene regulation in the immune system', Histones: Class, Structure and Function, Nova Science Publishers, CH Shen (ed), New York, United States, pp. 185-200. ISBN 978-1-62100-274-1 (2012) [Research Book Chapter]

[eCite] [Details]

Co-authors: Apps LD

Tweet

2011Marthick JR, Holloway AF, Dickinson JL, 'Integrins as determinants of genetic susceptibility, tumour behaviour and their potential as therapeutic targets', Prostate Cancer - From Bench to Bedside, InTech, Philippe E. Spiess (ed), Rijeka, Croatia, pp. 243-266. ISBN 978-953-307-331-6 (2011) [Research Book Chapter]

DOI: 10.5772/1285 [eCite] [Details]

Co-authors: Marthick JR; Dickinson JL

Tweet

2011Poke FS, Holloway AF, 'Chemoprevention Targeting Epigenetic Changes in Cancer', Field Cancerization: Basic Science and Clinical Applications, Nova Science Publishers, Gabriel D. Dakubo (ed), New York, pp. 559-575. ISBN 978-1-61761-006-6 (2011) [Research Book Chapter]

[eCite] [Details]

Co-authors: Poke FS

Tweet

2001Shannon MF, Holloway AF, 'Chromatin remodelling and transcriptional regulation of cytokine gene transcription in T cells', Cytokines and Autoimmune Disease, Humana Press, VK Kuchroo, D Hafler, N Sarvetnick and LB Nicholson (ed), Totowa, NJ, USA, pp. 25-48. ISBN 1-59259-129-9 (2001) [Research Book Chapter]

[eCite] [Details]

1999West AK, Holloway AF, Stennard FA, Miller JM, 'Metallothionein expression in the mammalian brain', Metallothionein IV, Birkh user, CD Klaassen (ed), Boston, pp. 377-382. ISBN 0-8176-6830-0 (1999) [Research Book Chapter]

[eCite] [Details]

Co-authors: West AK; Stennard FA; Miller JM

Conference Publication

(19 outputs)
YearCitationAltmetrics
2018Chapman J, Douglas T, Choi-Lundberg DL, Holloway AF, 'What HAPpened? Lessons learned from introducing first-year cross-campus, consolidated Human Anatomy and Physiology (HAP) units', Teaching Matters 2018, 21 November 2018, Launceston, Tasmania (2018) [Conference Extract]

[eCite] [Details]

Co-authors: Chapman J; Douglas T; Choi-Lundberg DL

2018Chapman JA, Douglas T, Choi-Lundberg DL, Holloway AF, 'What HAPpened? Lessons learned from introducing flipped classroom to two first-year cross-campus, Human Anatomy and Physiology (HAP) units', ANZACA 2018, 3-5 December 2018, James Cook University, Australia (2018) [Conference Extract]

[eCite] [Details]

Co-authors: Chapman JA; Douglas T; Choi-Lundberg DL

2011Chin PS, Short AK, West AC, Marthick JR, Holloway AF, et al., 'Regulation of the ITGA2 gene in prostate cancer', Lorne Cancer Conference , February, Lorne, Victoria (2011) [Conference Extract]

[eCite] [Details]

Co-authors: Chin PS; Short AK; West AC; Marthick JR; Dickinson JL

2009Short AK, West AC, Patterson B, Polanowski A, Holloway AF, et al., 'Methylation of the ITGA2 promoter in Prostate Cancer', Epigenetics Conference, Melbourne, Australia (2009) [Conference Extract]

[eCite] [Details]

Co-authors: Short AK; West AC; Patterson B; Polanowski A; Dickinson J

2005Brettingham-Moore KH, Ray SN, Holloway AF, 'A role for the BAF remodelling complex in GM-CSF gene regulation', ComBio 2005 Combined Conference Abstracts, 25-29 Sep 2005, Adelaide, pp. 51. (2005) [Conference Extract]

[eCite] [Details]

Co-authors: Brettingham-Moore KH; Ray SN

2005Brettingham-Moore KH, Shannon MF, Holloway AF, 'GM-CSF gene activation; providing an insight into the role of BRG1 in gene regulation', Mechanisms of Eukaryotic Transcription, 31 Aug - 4 Sep 2005, pp. 44. (2005) [Conference Extract]

[eCite] [Details]

Co-authors: Brettingham-Moore KH

2005Brettingham-Moore KH, Shannon MF, Holloway AF, 'Transcription factors and chromatin remodelers involved in activating the GM-CSF gene', The Genome Conference, 13-17 Feb 2005, Victoria, pp. 101. (2005) [Conference Extract]

[eCite] [Details]

Co-authors: Brettingham-Moore KH

2005Oakford PC, Holloway AF, 'Regulation of gene expression by the RUNX-1 transcription factor', The Genome Conference, 13-17 Feb 2005, Victoria, pp. 108. (2005) [Conference Extract]

[eCite] [Details]

Co-authors: Oakford PC

2004Brettingham-Moore KH, Holloway AF, 'A role for the NF-KB family member, Crel, in chromatin remodelling events at the GM-CSF promotor', ComBio 2004, 26-30 Sept 2004, Perth, pp. 82. (2004) [Conference Extract]

[eCite] [Details]

Co-authors: Brettingham-Moore KH

2004Brettingham-Moore KH, Shannon MF, Holloway AF, 'GM-CSF promotor remodeling and gene transcription in response to T cell activation are distinct events', The Genome Conference, 15-19 Feb 2004, Lorne, Vic (2004) [Conference Extract]

[eCite] [Details]

Co-authors: Brettingham-Moore KH

2004Brettingham-Moore KH, Shannon MF, Holloway AF, 'Distinct signals and factors are required for GM-CSF promotor chromatin remodelling and gene transcription', ComBio 2004, 26-30 Sept 2004, Perth, pp. 46. (2004) [Conference Extract]

[eCite] [Details]

Co-authors: Brettingham-Moore KH

2003Brettingham-Moore KH, Rao S, Shannon MF, Holloway AF, 'Disecting the molecular events involved in activation of GM-CSF gene expression in T cells', 24th Annual Conference on the Organisation and Expression of the Genome, 16-20 Feb 2003, Lorne, Victoria, pp. Poster 1-25. ISBN 0-9585259-0-0 (2003) [Conference Extract]

[eCite] [Details]

Co-authors: Brettingham-Moore KH

2003Brettingham-Moore KH, Shannon MF, Holloway AF, 'Defining the molecular events required for GM-CSF gene activation in T cells', ComBio 2003 Combined Conference Abstracts, 9 Sept-2 Oct 2003, pp. 161. (2003) [Conference Extract]

[eCite] [Details]

Co-authors: Brettingham-Moore KH

2003Juelich T, Milburn P, Holloway AF, Shannon F, 'Proteomics approach for identification of coactivators complexes interacting with transcription factors at the hGM-CSF promotor', 24th Annual Conference on the Organisation and Expression of the Genome, 16-20 Feb 2003, Lorne, Victoria, pp. Poster 1-8. ISBN 0-9585259-0-0 (2003) [Conference Extract]

[eCite] [Details]

2002Holloway AF, Rao S, Brettingham-Moore KH, Shannon MF, 'Selective remodelling of a single nucleosome precedes GM-CSF transcription in T cells', Proceedings of the Australian Society for Biochemistry and Molecular Biology, 29 September - 3 October, 2002, Sydney, pp. sym-58-04. (2002) [Conference Extract]

[eCite] [Details]

Co-authors: Brettingham-Moore KH

1999West AK, Holloway AF, How JD, Adlard PA, Vickers JC, 'Structure and synthesis of the neuroactive metallothionein isoform, MTIII (Growth Inhibitory Factor)', HGM'99, 27-30 March 1999, Brisbane, pp. 85. (1999) [Conference Extract]

[eCite] [Details]

Co-authors: West AK; Vickers JC

1997West AK, Holloway AF, 'Metallothionein expression in the developing sheep brain', European Commission, Joint Research Centre, Geel, Belgium, pp. 35. (1997) [Conference Edited]

[eCite] [Details]

Co-authors: West AK

1995Holloway AF, Stennard FA, West AK, 'Expression of mammalian metallothioneins during development', Congress of the European Developmental Biology Organisation, Toulouse, France, pp. 135. (1995) [Conference Extract]

[eCite] [Details]

Co-authors: Stennard FA; West AK

1995Holloway AF, Stennard FA, West AK, 'Expression of metallothionein isoforms in mammals', Lorne Genome Conference, Lorne, Vic, pp. 1-48. (1995) [Conference Extract]

[eCite] [Details]

Co-authors: Stennard FA; West AK

Thesis

(1 outputs)
YearCitationAltmetrics
1997Holloway AF, 'Structure and expression of mammalian metallothioneins' (1997) [PhD]

[eCite] [Details]

Other Public Output

(1 outputs)
YearCitationAltmetrics
2003Holloway AF, 'Research on the Apple Isle', Australian Biochemist, Australian Society for Biochemistry and Molecular Biology, Sydney, 34, 2 (2003) [Magazine Article]

[eCite] [Details]

Grants & Funding

Dr Holloway has had continuous external research funding since establishing her research group at the University of Tasmania in 2002, including from NHMRC as well as other research foundations.

Funding Summary

Number of grants

52

Total funding

$3,676,976

Projects

Gaining new insights into metastatic bone tumours (2020)$24,925
Description
Molecular analysis of prostate cancer tumour specimen to identify new molecular targets for therapy.
Funding
Royal Hobart Hospital Research Foundation ($24,925)
Scheme
Grant-Project
Administered By
University of Tasmania
Research Team
Dickinson JL; Holloway AF; Nott LM; Liu G; Fitzgerald LM; Brettingham-Moore KH; Hewitt A; Taberlay PC
Year
2020
The impact of repeated DNA damage on the molecular profile of prostate cancer cells (2019)$23,295
Description
Many cancer patients receive fractionated/recurrent dosages of DNA damaging agents and there is some evidence that this may drive future treatment resistance and metastasis. This project will profile prostate cancer cells after repeated DNA damage via RNA-seq and EPIC arrays
Funding
Royal Hobart Hospital Research Foundation ($23,295)
Scheme
Grant-Project
Administered By
University of Tasmania
Research Team
Brettingham-Moore KH; Black Allison; Taberlay PC; Holloway AF
Year
2019
Identifying the Underlying Genetic Drivers of IPF using Complementary Approaches (2018 - 2022)$1,174,559
Description
In the first instance the goal is to define the contribution of genetic variants to IPF in the Australian population, and we are in a unique position in Australia through our collaboration with Professor Schwartz. Our focus in this particular project is on rare genetic variation, and whilst it is likely that common variation will be similar to other mostly Caucasian populations there are likely to be differences in the rare variants in genes contributing to disease in the different populations. It is therefore important that these types of studies are performed in our population if we are going to understand the biology of disease in our patients. As discussed the identification of rare variants underpinning complex disease is proving fruitful both in understanding the biology of disease, the spectrum of clinical manifestations observed and importantly providing new potential targets for therapy.
Funding
Lung Foundation Australia ($1,174,559)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Corte T; Holloway AF; Charlesworth JC; Walters EH; Wood-Baker R
Period
2018 - 2022
A Clinical and Biospecimens Prostate Cancer Resource for Biomarker Research in Tasmania (2018)$22,146
Description
We propose to build upon the clinically-focused Prostate Cancer Outcomes Registry, Tasmania (PCOR-TAS) and collect matched biological samples to create a valuable resource for both clinicians and scientists. The availability of clinical and genetic data will allow important biomarker research into predicting prostate cancer outcomes and improving treatment strategies.
Funding
Royal Hobart Hospital Research Foundation ($22,146)
Scheme
Grant-Minor Project
Administered By
University of Tasmania
Research Team
Fitzgerald LM; Dickinson JL; Skala M; Stokes BC; Donovan S; Malley RC; Redwig F; Holloway AF; Taberlay PC
Year
2018
Mapping epigenomic information in a three-dimensional prostate cancer cell environment (2017)$20,990
Description
We lack a model that better replicates in vivo tumour development to study epigenomic mechanisms of prostate cancer. To date, epigenetic changes in cancer have been investigated in homogenous cell lines from two-dimensional laboratory cultures or end-point tumour samples (static) from patients. Without doubt these studies have provided great insight into epigenetic differences that distinguish cancer cells from normal cells. However, there is a glaring lack of information about dynamic and temporal changes to the epigenome and cell behaviour as the cells acquire invasive potential. This is not possible using currently available two-dimensional models and clinical samples. We will address this deficit by establishing a three-dimensional model of prostate cancer that allows us to map how epigenomes and cell behaviours change during cancer development.
Funding
Cancer Council of Tasmania ($20,990)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Taberlay PC; Brettingham-Moore KH; Holloway AF; Biro M
Year
2017
Developing CRISPR/Cas Library Screens for identifying Novel Cancer Therapies (2017)$63,845
Description
Our understanding of many cancers has improved dramatically over the past decade predominantly due to our ability to sequence entire genomes, at scale. Yet, we still require a better understanding of the underlying mechanisms that initiate and perpetuate cancers, as well as gene-based factors that initiate the transition from indolent to aggressive cancers with a propensity to metastasize. CRISPR/Cas is proving a robust, powerful and necessary tool in the laboratory that will undoubtedly underpin the next breakthrough in the field of cancer. As such, it is essential that we develop this capability at the University of Tasmania in a timely manner.The specific AIMS of this proposal are to:Aim 1: Establish CRISPR/Cas screening at the University of Tasmania as a tool to identify genesthat drive aggressive and metastatic cancers.Aim 2: Perform a genome-wide CRISPR/Cas negative selection (loss-of-function) screen toidentify genes essential for proliferation and survival, as well as metastatic behaviour.
Funding
University of Tasmania Foundation Inc ($63,845)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Taberlay PC; Hewitt A; Holloway AF; Liu G; Dickinson JL; Brettingham-Moore KH; Fitzgerald L; Eri RD; Cook AL
Year
2017
David Collins Leukaemia Foundation Elite Research Scholarship - Epigenetic and Transcriptional regulation of leukaemia (2016 - 2019)$153,000
Description
This project will investigate how epigenetic and transcription factors co-operate to control gene expression, how this is reprogrammed in leukaemia and how epigenetic drugs impact these gene expression programs.
Funding
David Collins Leukaemia Foundation ($153,000)
Scheme
Donation - Individual
Administered By
University of Tasmania
Research Team
Holloway AF; Dickinson JL; Brettingham-Moore KH
Period
2016 - 2019
Molecular profiling of the post radiotherapy chromatin landscape in prostate cancer cells (2016)$33,000
Description
This project will investigate the basal and post radiotherapy epigenetic changes in prostate cancer cells with divergent response to radiotherapy (RT). It will validate methylation data obtained from illumina Infinium 450 beadchip arrays, profile histone modifications post RT and investigate DNA damage post RT in cells treated with inhibitors of epigenetic enzymes (DNMT and HDAC).
Funding
Cancer Council of Tasmania ($33,000)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Brettingham-Moore KH; Ambrose M; Holloway AF; Skala M; Taberlay PC
Year
2016
Exploring the mechanisms responsible for the early transformation from chronic colitis to colorectal cancer (2016)$28,000
Description
This project will be the first study to model early changes in inflammation-associated colitis without the need for carcinogentreatment, which mirrors the clinical situation of human colitis. The project will study the histological and biochemical changes associated with the development of colorectal cancer in this mouse model that closely resembles the development seen in humans. The project will also investigate the mirobiome changes in the progression.
Funding
Cancer Council of Tasmania ($28,000)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Kunde DA; Eri RD; Holloway AF
Year
2016
Bi-functional opioids as a novel cancer treatment (2015)$6,567
Description
The aim of our study is to assess the anticancer effect of our 10 novel opioid drugs in six different intestinal cancer cell lines and compare them with oxaliplatin and irinotecan. The particular objectives of the study are:1. To evaluate the effect of our novel drugs on intestinal cancer cell viability, growth, proliferation and ability to form colonies.2. To explore the molecular mechanisms of the anticancer activity of our novel drugs.
Funding
Cancer Council of Tasmania ($6,567)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dietis ND; Liu JJ; Holloway AF; Guven N
Year
2015
Epigenetic regulation of inegrin beta 4 as a predictor of prostate cancer progression (2015)$14,750
Description
Prostate cancer diagnoses continue to rise rapidly in Australia, but of most concern is ourcurrent inability to distinguish aggressive tumours with propensity to metastasize from moreindolent disease. This results in unnecessary treatment of many men whose cancer may neverprogress to clinically significant disease. However, progression of the disease results in aggressive, metastatic tumours which are difficult to treat and are associated with poor prognosis. We thus urgently require a better understanding of the underlying drivers of this disease, and particularly the factors and mechanisms that drive the transition to more aggressive tumours with a propensity to spread. These factors may represent biomarkers and potential therapeutic targets in prostate cancer progression.The aims of this study are therefore:1.To determine whether epigenetic changes at the ITGB4 gene are associated with its increased expression in prostate cancer progression, and 2. To investigate whether epigenetic changes at the ITGB4 gene in prostate cancer are driven by the RUNX transcription factors.
Funding
Cancer Council of Tasmania ($14,750)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Holloway AF; Dickinson JL; Brettingham-Moore KH; Rao S; Black Allison
Year
2015
Embedding the benefits of undergraduate research experiences for medical research and health professional students (2015)$30,000
Description
The purpose of the project is to improve expectations and outcomes of research experiences in undergraduate medical research and health professional students.The project team will analyse the student responses, comparing theseto existing TREASURE data and evaluating student perceptions andlearning1, 2. Our improved understanding of how students perceiveresearch in the context of the health professions will be used todevelop scaffolded approaches to undergraduate research, to betterinform student expectations and better prepare students forundergraduate research experiences.
Funding
Office for Learning & Teaching ($30,000)
Scheme
Grant-Extension Funding
Administered By
University of Tasmania
Research Team
Holloway AF; Williams A-MM; Radford JC; Ogden K; Clegg L; Howitt S
Year
2015
Familial Haematological Malignancies: understanding the role of inherited causative factors (2014)$20,000
Description
Genetic factors are known to contribute to the risk of developing haematological malignancies, however to date the underlying genetic drivers of disease development remain largely unknown. Knowing the causative genes is not only important in understanding the disease process but also provides a range of benefits in the diagnosis, development of tailored treatments, and identification of new targets for therapy. Studying families with multiple cases of these diseases is a powerful approach used to identify the causative genes.
Funding
Cancer Council of Tasmania ($20,000)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Charlesworth JC; Foote SJ; Thomson RJ; Holloway AF; Lowenthal RM
Year
2014
Intersection of RUNX and integrin families in leukaemia (2014 - 2015)$30,000
Funding
David Collins Leukaemia Foundation ($30,000)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Holloway AF; Dickinson JL
Period
2014 - 2015
The role of epigenetic changes in the progression of clinical disease in Multiple Endocrine Neoplasia Type 1 (MEN 1) (2013)$22,500
Funding
Royal Hobart Hospital Research Foundation ($22,500)
Scheme
Grant-Research
Administered By
University of Tasmania
Research Team
Burgess JR; Prentice L; Holloway AF; Dickinson JL
Year
2013
Combining deep sequencing and linkage approaches to identify rare variants contributing to familial prostate cancers (2013 - 2014)$35,000
Funding
Cancer Council of Tasmania ($35,000)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Thomson RJ; Charlesworth JC; Holloway AF; Jarman SN
Period
2013 - 2014
Regulation of integrins by RUNX1 in leukaemia (2013)$30,000
Funding
David Collins Leukaemia Foundation ($30,000)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Holloway AF; Dickinson JL; Brettingham-Moore KH
Year
2013
Regulation of Integrin Gene Expression Programs by RUNX in Cancer (2013 - 2016)$26,250
Description
The incidence of leukaemia continues to increase in Tasmania despite advances in our understanding and treatment of the disease. A gene which is often disrupted in leukaemia is a master regulator called RUNX1, which controls how and when other genes are switched on in blood cells. This project hypothesises that RUNX1 controls cell surface molecules called integrins. It proposes that disruption of RUNX1 in blood cells leads to the development of leukaemia by altering the integrins on the surface of the cells.
Funding
Cancer Council of Tasmania ($26,250)
Scheme
Scholarship-PhD Top-Up Grant
Administered By
University of Tasmania
Research Team
Holloway AF; Dickinson JL
Period
2013 - 2016
Regulation of gene expression in cancer (2012 - 2013)$4,500
Funding
Donation via University of Tasmania Foundation ($4,500)
Scheme
Donation - Individual
Administered By
University of Tasmania
Research Team
Holloway AF
Period
2012 - 2013
Prostate cancer risk variants in integrin genes & their role in prostate cancer development (2012)$49,362
Funding
Cancer Council of Tasmania ($49,362)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Holloway AF; McMorran BJ; Thomson RJ
Year
2012
Epigenetic regulation of T-cell gene expression programs (2012)$8,505
Funding
The Select Foundation ($8,505)
Scheme
Grant-Small Grants Scheme
Administered By
University of Tasmania
Research Team
Holloway AF; Korner H
Year
2012
Epigenetic Regulation of Tumour Supressors in Skin Cancer (2012)$22,300
Funding
Cancer Council of Tasmania ($22,300)
Scheme
Grant-Small
Administered By
University of Tasmania
Research Team
Cook AL; Snow ET; Holloway AF
Year
2012
Epigenomics of familial prostate cancer (2011)$14,000
Funding
Cancer Council of Tasmania ($14,000)
Scheme
Grant-Small
Administered By
University of Tasmania
Research Team
Charlesworth JC; Holloway AF; Dickinson JL
Year
2011
Prostate cancer risk variants in integrin genes and their role in tumour development (2011)$10,000
Funding
Cancer Council of Tasmania ($10,000)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Holloway AF; McMorran BJ; Patterson B; Thomson RJ
Year
2011
Epigenetic Regulation of the integrin, ITGA2, in Tumour Development (2011)$10,000
Funding
Cancer Council of Tasmania ($10,000)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Holloway AF
Year
2011
Transcriptome analysis for predicting response to radiotherapy in prostate cancer patients (2011)$9,091
Funding
Royal Hobart Hospital Research Foundation ($9,091)
Scheme
Grant-Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Brettingham-Moore KH; Skala M; Holloway AF; Stankovich J
Year
2011
Regulation of the LIFR Receptor by RUNX1 (2011)$49,500
Funding
David Collins Leukaemia Foundation ($49,500)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Holloway AF; Tegg EM
Year
2011
Rising Stars 3 (2011 - 2013)$51,000
Funding
University of Tasmania ($51,000)
Scheme
Grant-Rising Stars Round 3
Administered By
University of Tasmania
Research Team
Holloway AF
Period
2011 - 2013
Upgrade of the flow cytometry facility of the Menzies Research Institute with a multi-parameter analytical flow cytometer CyAn ADP 9 Color for key applications (2011)$75,000
Funding
Clive & Vera Ramaciotti Foundation ($75,000)
Scheme
Grant-Equipment
Administered By
University of Tasmania
Research Team
Korner H; McMorran BJ; Woods GM; Holloway AF; West AK
Year
2011
ITGA2: characterisation as a potential biomarker in prostate cancer (2010)$48,125
Funding
Cancer Council of Tasmania ($48,125)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Holloway AF; Patterson B; Stankovich J; McMorran BJ
Year
2010
Regulation of the Leukaemia Inhibitory Factor Receptor complex by RUNX1 (2010)$48,950
Funding
David Collins Leukaemia Foundation ($48,950)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Holloway AF
Year
2010
Elucidation of the role of the integrin alpha 2 gene (ITGA2) in prostate cancer (2009)$45,600
Funding
Cancer Council of Tasmania ($45,600)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Holloway AF; Patterson B; Stankovich J; McMorran BJ
Year
2009
Investigating novel targets of the RUNX1 transcription factor (2009)$10,000
Funding
David Collins Leukaemia Foundation ($10,000)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Holloway AF
Year
2009
Elucidation of the role of a novel susceptibility gene in prostate cancer (2008)$25,000
Funding
Cancer Council of Tasmania ($25,000)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Holloway AF; Patterson B; McMorran BJ; Stankovich J
Year
2008
Elucidation of the role of a novel susceptibility gene in prostate cancer (2008)$25,000
Funding
Royal Hobart Hospital Research Foundation ($25,000)
Scheme
Grant-Research
Administered By
University of Tasmania
Research Team
Dickinson JL; Holloway AF; Patterson B; McMorran BJ; Stankovich J
Year
2008
Characterising aberrant RUNX1 transcriptional complexes (2008)$20,000
Funding
David Collins Leukaemia Foundation ($20,000)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Holloway AF
Year
2008
How does basal chromatin structure predict cytokine gene responses (2008 - 2010)$501,000
Funding
National Health & Medical Research Council ($501,000)
Scheme
Grant-Project
Administered By
University of Tasmania
Research Team
Holloway AF; Shannon MF
Period
2008 - 2010
Grant Reference
490014
Scarring and angiogenesis in the airway wall in smoking and COPD: links between inflammation and remodelling (2008 - 2010)$347,125
Funding
National Health & Medical Research Council ($347,125)
Scheme
Grant-Project
Administered By
University of Tasmania
Research Team
Walters EH; Wood-Baker R; Reid DW; Muller HK; Holloway AF
Period
2008 - 2010
Grant Reference
490023
Silencing the AML1/ETO fusion gene as a treatment strategy for acute myeloid leukaemia (2008)$7,704
Funding
Clifford Craig Foundation ($7,704)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Woods GM; Holloway AF; Casey NP
Year
2008
Deregulation of Gene Expression by RUNX1 Fusion Proteins in Leukaemia (2007)$25,000
Funding
David Collins Leukaemia Foundation ($25,000)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Holloway AF
Year
2007
Switching genes on in immune cells: how does basal chromatin structure predict cytokine gene responses? (2007)$20,000
Funding
Royal Hobart Hospital Research Foundation ($20,000)
Scheme
Grant-Research
Administered By
University of Tasmania
Research Team
Holloway AF; Shannon MF; Walters EH
Year
2007
EMBO Conference on Chromatin and Epigenetics attendance (2007)$1,200
Funding
Cancer Council of Tasmania ($1,200)
Scheme
Grant-Travel
Administered By
University of Tasmania
Research Team
Holloway AF; Taberlay PC
Year
2007
Philippa Oakford: Epigenetics 2007 Australian Scientific Conference (2007)$400
Funding
David Collins Leukaemia Foundation ($400)
Scheme
Award-Professional Development
Administered By
University of Tasmania
Research Team
Holloway AF; Taberlay PC
Year
2007
Investigating the Role of the RUNX1 Protein in the Regulation of Gene Expression in Myeloid Cells (2006)$25,000
Funding
David Collins Leukaemia Foundation ($25,000)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Holloway AF
Year
2006
Luminometry System (2006)$22,300
Funding
National Health & Medical Research Council ($22,300)
Scheme
Grant-Equipment
Administered By
University of Tasmania
Research Team
Holloway AF; West AK; Chung RS
Year
2006
Grant Reference
361670
Leica DMIRB Inverted Microscope Configured for Fluorescence and Bright Field with Phase Contrast (2005)$10,000
Funding
National Health & Medical Research Council ($10,000)
Scheme
Grant-Equipment
Administered By
University of Tasmania
Research Team
Chuah MI; West AK; Holloway AF; Rattigan S; Richards SM; Chung RS; Foa LC
Year
2005
Grant Reference
264668
Identifying Genes Regulated by AML1 in Myeloid Cells (2005)$28,000
Funding
David Collins Leukaemia Foundation ($28,000)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Holloway AF; Rao S
Year
2005
Role of NF-kB Remodelling Complexes in Inducible Gene Expression in T Cells (2004 - 2006)$239,750
Funding
National Health & Medical Research Council ($239,750)
Scheme
Grant-Project Three Year
Administered By
University of Tasmania
Research Team
Holloway AF; Shannon MF
Period
2004 - 2006
Grant Reference
302202
Regulation of Gene Expression by the AML1 Transcription Factor in Myeloid Cells (2004)$28,380
Funding
David Collins Leukaemia Foundation ($28,380)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Holloway AF
Year
2004
Refrigerated Benchtop Centrifuge (2004)$12,941
Funding
National Health & Medical Research Council ($12,941)
Scheme
Grant-Equipment
Administered By
University of Tasmania
Research Team
Holloway AF; West AK; Chuah MI; Rattigan S; Richards SM
Year
2004
Grant Reference
264536
Development of a Screen for AML1 Target Genes (2003)$8,416
Funding
Royal Hobart Hospital Research Foundation ($8,416)
Scheme
Grant-Research
Administered By
University of Tasmania
Research Team
Holloway AF; Ragg SJ
Year
2003
A Functional Proteomics Approach to the Study of Inducible Gene Transcription in a Chromatin Context (2002 - 2004)$115,000
Funding
National Health & Medical Research Council ($115,000)
Scheme
Grant-Project
Administered By
Australian National University
Research Team
Shannon MF; Holloway AF
Period
2002 - 2004

Research Supervision

Dr Holloway has extensive experience as a supervisor of PhD and Honours students, with her completed PhD students going on to undertake postdoctoral studies in highly successful research groups in Australia, USA and UK.

Current

5

Completed

13

Current

DegreeTitleCommenced
PhDTranscriptomic and DNA Methylation Alterations in Prostate Cancer Metastasis2016
PhDTranscriptional and Epigenetic Regulation of Tumour Development and Metastasis2017
PhDEpigenetic Determinants of Metastasis in Breast Cancer2018
PhDLeadership Development: Understanding the missing link in Health and Human Services workforce development2020
PhDEpigenetic Evolution During Cancer Treatment2020

Completed

DegreeTitleCompleted
PhDGene Regulation by RUNX1 in the Absence of Consensus Sequences
Candidate: Alexandra Morgan Woodworth
2020
PhDUsing Families to Understand the Impact of Genetic Variation on Prostate Cancer
Candidate: Kelsie Raspin
2020
PhDRegulation of ITGA6 and ITGB4 Integrin Genes by RUNX1 and Epigenetic Mechanisms
Candidate: Jessica Louise Phillips
2017
PhDEpigenomic and Genomic Analysis of Familial Prostate Cancer
Candidate: Emma Cazaly
2017
PhDThe Anti-Cancer Activity of the Natural Product, Fucoidan, in Haematological Malignancies
Candidate: Farzaneh Atashrazm
2016
PhDMolecular Mechanisms Used by Staphylococcus Aureus to Access Iron from Human Haemoglobin
Candidate: Claire Frances Dickson
2014
PhDEpigenetic mechanisms of arsenic-induced transformation in human keratinocytes
Candidate: Katharine Jane Herbert
2014
PhDRegulation of the ITGA2 Gene in Prostate Cancer
Candidate: Suyin Paulynn Chin
2014
PhDRegulation of Inducible Immune Gene Expression in T Cells Compared to Macrophages
Candidate: Lucy Damaris Apps
2014
PhDRegulation of the LIFR and gp130 Genes by the RUNX1 Transcription Factor
Candidate: Abeer Ahmed Qadi
2012
PhDDifferential Expression of the GM-CSF Gene in the Immune System is Regulated By Epigenetic Factors
Candidate: Owen Ralph Sprod
2011
PhDRegulation of Gene Expression by the RUNX1 Transcription Factor
Candidate: Phillippa Claire Oakford
2008
PhDDefining the Molecular Events Required for GM-CSF Gene Activation in T Cells
Candidate: Kate Brettingham-Moore
2006